Madrigal Pharmaceuticals, Inc. Common Stock (MDGL) Stock Price

MDGLStock

$532.36+22.09%52W

Market Cap$12.30B

P/E—

PEG Ratio—

Div yield—

Beta-1.12

MDGL Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)9.38%

Price vs S&P 500 (4W)9.20%

VGM Score57.55

Book Value / Share (Quarterly)$22.68

P/TBV (Annual)22.22x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-9.06

Price vs S&P 500 (YTD)-21.16%

Gross Margin (TTM)91.48%

Net Profit Margin (TTM)-25.32%

EPS (TTM)$-12.87

10-Day Avg Trading Volume0.25M

EPS Excl Extra (TTM)$-12.87

EPS (Annual)$-12.85

ROI (Annual)-30.58%

Gross Margin (Annual)94.14%

Net Profit Margin (5Y Avg)-12793.16%

Cash / Share (Quarterly)$36.32

Revenue Growth QoQ (YoY)71.17%

ROA (Last FY)-22.89%

Revenue Growth TTM (YoY)149.04%

EBITD / Share (TTM)$-12.50

ROE (5Y Avg)-94.94%

Operating Margin (TTM)-25.34%

Cash Flow / Share (Annual)$-8.45

P/B Ratio22.39x

P/B Ratio (Quarterly)23.64x

Net Income / Employee (Annual)$-315,100

EV / Revenue (TTM)9.17x

Net Interest Coverage (TTM)-163.11x

ROA (TTM)-25.53%

EV / EBITDA (TTM)710.53x

EPS Incl Extra (Annual)$-12.85

Current Ratio (Annual)4.01x

Quick Ratio (Quarterly)2.76x

3-Month Avg Trading Volume0.33M

52-Week Price Return22.09%

Revenue / Employee (TTM)$1,403,200

Tangible BV / Share (Quarterly)$22.37

P/S Ratio (Annual)12.23x

Asset Turnover (Annual)0.76x

52-Week High$615.00

Operating Margin (5Y Avg)-12410.94%

EPS Excl Extra (Annual)$-12.85

CapEx CAGR (5Y)60.06%

Tangible BV CAGR (5Y)1.61%

26-Week Price Return21.31%

Quick Ratio (Annual)3.62x

13-Week Price Return3.45%

Total Debt / Equity (Annual)0.56x

Current Ratio (Quarterly)3.20x

Enterprise Value$11.77B

Asset Turnover (TTM)1.01x

Book Value / Share Growth (5Y)11.25%

Revenue / Employee (Annual)$1,047,400

Pretax Margin (Annual)-30.08%

Cash / Share (Annual)$43.06

3-Month Return Std Dev47.13%

Net Income / Employee (TTM)$-355,300

ROE (Last FY)-47.83%

Net Interest Coverage (Annual)-68.31x

EPS Basic Excl Extra (Annual)$-12.85

P/FCF (TTM)123.34x

Receivables Turnover (TTM)9.46x

Total Debt / Equity (Quarterly)0.65x

EPS Incl Extra (TTM)$-12.87

Receivables Turnover (Annual)10.18x

ROI (TTM)-35.56%

P/S Ratio (TTM)9.13x

Pretax Margin (5Y Avg)-12793.16%

Revenue / Share (Annual)$42.72

Tangible BV / Share (Annual)$26.06

Forward P/E182.85x

Price vs S&P 500 (52W)3.54%

Year-to-Date Return-8.34%

5-Day Price Return4.26%

EPS Normalized (Annual)$-12.85

ROA (5Y Avg)-59.17%

Net Profit Margin (Annual)-30.08%

Month-to-Date Return14.22%

Cash Flow / Share (TTM)$-19.21

EBITD / Share (Annual)$-13.43

Operating Margin (Annual)-31.60%

LT Debt / Equity (Annual)0.56x

ROI (5Y Avg)-79.76%

LT Debt / Equity (Quarterly)0.65x

EPS Basic Excl Extra (TTM)$-12.87

P/TBV (Quarterly)23.97x

P/B Ratio (Annual)21.94x

Inventory Turnover (TTM)1.34x

Pretax Margin (TTM)-25.32%

Book Value / Share (Annual)$26.39

Price vs S&P 500 (13W)1.50%

Beta-1.12x

P/FCF (Annual)471.47x

Revenue / Share (TTM)$44.05

ROE (TTM)-56.65%

52-Week Low$393.61

vGradeD

gGradeA

mGradeB

vgmGradeC

MDGL Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Jul 30, 2026	-$2.23	-$1.99	+10.76%(+$0.24)
Q1 2026	May 6, 2026	-$4.14	-$1.38	+66.70%(+$2.76)
Q4 2025	Feb 19, 2026	-$0.88	-$2.57	-192.20%(-$1.69)
Q3 2025	Nov 4, 2025	-$1.99	-$4.96	-148.77%(-$2.96)
Q2 2025	Aug 5, 2025	-$3.53	-$1.90	+46.21%(+$1.63)

MDGL Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.09

4.08

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$532.36
LLYEli Lilly & Co.	D	B	C	$1157.72
JNJJohnson & Johnson	D	C	B	$266.25
ABBVABBVIE INC.	D	C	B	$256.25
MRKMerck & Co., Inc.	D	C	B	$147.86
NVSNovartis AG	C	C	C	$152.25
AZNAstraZeneca PLC	C	B	C	$162.31
NVONovo-Nordisk A/S	B	C	C	$45.55
ABTAbbott Laboratories	C	C	C	$110.17
PFEPfizer Inc.	C	D	B	$28.36
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.37
BMYBristol-Myers Squibb Co.	B	B	B	$66.56
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.51
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.44
REGNRegeneron Pharmaceuticals Inc	C	C	B	$798.22
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$17.98
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$35.97
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$355.89
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$61.27
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.06
ZTSZOETIS INC.	C	C	D	$76.98
INSMInsmed, Inc.	F	A	C	$120.45
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.13
UTHRUnited Therapeutics Corp	C	C	B	$511.00
GMABGenmab A/S ADS	C	C	B	$33.08
VTRSViatris Inc. Common Stock	B	C	B	$16.38
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$263.36
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$251.60
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.05
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$65.53
CORTCorcept Therapeutics Inc.	F	C	B	$112.56
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$23.96
ARWRArrowhead Research Corporation	D	A	B	$81.30
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.62
AXSMAxsome Therapeutics, Inc	D	B	C	$199.81
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.15
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$60.31
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
ABVXAbivax SA American Depositary Shares	—	—	C	$112.40
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$346.62
CYTKCytokinetics Inc.	F	D	C	$69.36
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.83
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.98
TGTXTG Therapeutics, Inc.	D	B	B	$53.41
ALKSAlkermes Inc. plc	D	C	B	$47.41
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$87.91
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$104.58
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$153.67
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.56
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	A	A	$78.05
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	C	C	B	$17.44

About Madrigal Pharmaceuticals, Inc. Common Stock

Madrigal Pharmaceuticals develops treatments for metabolic dysfunction-associated steatohepatitis (MASH), a progressive liver disease with significant unmet medical need. Its lead product, Rezdiffra (resmetirom), is a once-daily, oral thyroid hormone receptor beta agonist designed to address the underlying causes of MASH and prevent progression to cirrhosis and liver failure.